240 related articles for article (PubMed ID: 17006265)
1. Rituximab (anti-CD20) adjunctive therapy for opsoclonus-myoclonus syndrome.
Pranzatelli MR; Tate ED; Travelstead AL; Barbosa J; Bergamini RA; Civitello L; Franz DN; Greffe BS; Hanson RD; Hurwitz CA; Kalinyak KA; Kelfer H; Khakoo Y; Mantovani JF; Nicholson SH; Sanders JM; Wegner S
J Pediatr Hematol Oncol; 2006 Sep; 28(9):585-93. PubMed ID: 17006265
[TBL] [Abstract][Full Text] [Related]
2. B cell depletion therapy for new-onset opsoclonus-myoclonus.
Pranzatelli MR; Tate ED; Swan JA; Travelstead AL; Colliver JA; Verhulst SJ; Crosley CJ; Graf WD; Joseph SA; Kelfer HM; Raju GP
Mov Disord; 2010 Jan; 25(2):238-42. PubMed ID: 20063398
[TBL] [Abstract][Full Text] [Related]
3. Immunologic and clinical responses to rituximab in a child with opsoclonus-myoclonus syndrome.
Pranzatelli MR; Tate ED; Travelstead AL; Longee D
Pediatrics; 2005 Jan; 115(1):e115-9. PubMed ID: 15601813
[TBL] [Abstract][Full Text] [Related]
4. [Opsoclonus myoclonus ataxia syndrome in Israel].
Blumkin L; Lerman-Sagie T
Harefuah; 2010 Jan; 149(1):24-8, 63. PubMed ID: 20422836
[TBL] [Abstract][Full Text] [Related]
5. CCR7 signaling in pediatric opsoclonus-myoclonus: upregulated serum CCL21 expression is steroid-responsive.
Pranzatelli MR; Tate ED; McGee NR; Ransohoff RM
Cytokine; 2013 Oct; 64(1):331-6. PubMed ID: 23764550
[TBL] [Abstract][Full Text] [Related]
6. Therapeutic down-regulation of central and peripheral B-cell-activating factor (BAFF) production in pediatric opsoclonus-myoclonus syndrome.
Pranzatelli MR; Tate ED; Hoefgen ER; Swan JA; Colliver JA
Cytokine; 2008 Oct; 44(1):26-32. PubMed ID: 18675552
[TBL] [Abstract][Full Text] [Related]
7. Opsoclonus-ataxia caused by childhood neuroblastoma: developmental and neurologic sequelae.
Mitchell WG; Davalos-Gonzalez Y; Brumm VL; Aller SK; Burger E; Turkel SB; Borchert MS; Hollar S; Padilla S
Pediatrics; 2002 Jan; 109(1):86-98. PubMed ID: 11773546
[TBL] [Abstract][Full Text] [Related]
8. CSF B-cell expansion in opsoclonus-myoclonus syndrome: a biomarker of disease activity.
Pranzatelli MR; Travelstead AL; Tate ED; Allison TJ; Verhulst SJ
Mov Disord; 2004 Jul; 19(7):770-777. PubMed ID: 15254934
[TBL] [Abstract][Full Text] [Related]
9. Evaluation of Responsiveness to Reduced-Dose Rituximab in Corticotropin/Intravenous Immunoglobulin/Rituximab Combination Immunotherapy for Opsoclonus-Myoclonus Syndrome.
Pranzatelli MR; Tate ED; McGee NR; MacArthur CA
Pediatr Neurol; 2018 Aug; 85():71-75. PubMed ID: 30197220
[TBL] [Abstract][Full Text] [Related]
10. Clinical stabilization and effective B-lymphocyte depletion in the cerebrospinal fluid and peripheral blood of a patient with fulminant relapsing-remitting multiple sclerosis.
Stüve O; Cepok S; Elias B; Saleh A; Hartung HP; Hemmer B; Kieseier BC
Arch Neurol; 2005 Oct; 62(10):1620-3. PubMed ID: 16216948
[TBL] [Abstract][Full Text] [Related]
11. Ofatumumab for a rituximab-allergic child with chronic-relapsing paraneoplastic opsoclonus-myoclonus.
Pranzatelli MR; Tate ED; Shenoy S; Travelstead AL
Pediatr Blood Cancer; 2012 Jun; 58(6):988-91. PubMed ID: 21618414
[TBL] [Abstract][Full Text] [Related]
12. Cerebrospinal fluid ACTH and cortisol in opsoclonus-myoclonus: effect of therapy.
Pranzatelli MR; Chun KY; Moxness M; Tate ED; Allison TJ
Pediatr Neurol; 2005 Aug; 33(2):121-6. PubMed ID: 16087057
[TBL] [Abstract][Full Text] [Related]
13. Dexamethasone, Intravenous Immunoglobulin, and Rituximab Combination Immunotherapy for Pediatric Opsoclonus-Myoclonus Syndrome.
Pranzatelli MR; Tate ED
Pediatr Neurol; 2017 Aug; 73():48-56. PubMed ID: 28651977
[TBL] [Abstract][Full Text] [Related]
14. CSF neurofilament light chain is elevated in OMS (decreasing with immunotherapy) and other pediatric neuroinflammatory disorders.
Pranzatelli MR; Tate ED; McGee NR; Verhulst SJ
J Neuroimmunol; 2014 Jan; 266(1-2):75-81. PubMed ID: 24342231
[TBL] [Abstract][Full Text] [Related]
15. Cerebrospinal fluid oligoclonal bands in childhood opsoclonus-myoclonus.
Pranzatelli MR; Slev PR; Tate ED; Travelstead AL; Colliver JA; Joseph SA
Pediatr Neurol; 2011 Jul; 45(1):27-33. PubMed ID: 21723456
[TBL] [Abstract][Full Text] [Related]
16. Functional characterisation of autoantibodies from patients with pediatric opsoclonus-myoclonus-syndrome.
Korfei M; Fühlhuber V; Schmidt-Wöll T; Kaps M; Preissner KT; Blaes F
J Neuroimmunol; 2005 Dec; 170(1-2):150-7. PubMed ID: 16203043
[TBL] [Abstract][Full Text] [Related]
17. Treatment of plasma cell dyscrasias by antibody-mediated immunotherapy.
Treon SP; Shima Y; Preffer FI; Doss DS; Ellman L; Schlossman RL; Grossbard ML; Belch AR; Pilarski LM; Anderson KC
Semin Oncol; 1999 Oct; 26(5 Suppl 14):97-106. PubMed ID: 10561024
[TBL] [Abstract][Full Text] [Related]
18. Effect of low-dose cyclophosphamide, ACTH, and IVIG combination immunotherapy on neuroinflammation in pediatric-onset OMS: A retrospective pilot study.
Pranzatelli MR; Allison TJ; Tate ED
Eur J Paediatr Neurol; 2018 Jul; 22(4):586-594. PubMed ID: 29555260
[TBL] [Abstract][Full Text] [Related]
19. Response to rituximab in 3 children with opsoclonus-myoclonus syndrome resistant to conventional treatments.
Battaglia T; De Grandis E; Mirabelli-Badenier M; Boeri L; Morcaldi G; Barabino P; Intra C; Naselli F; Pistoia V; Veneselli E; Conte M
Eur J Paediatr Neurol; 2012 Mar; 16(2):192-5. PubMed ID: 21737325
[TBL] [Abstract][Full Text] [Related]
20. Response to rituximab in a child with neuroblastoma and opsoclonus-myoclonus.
Bell J; Moran C; Blatt J
Pediatr Blood Cancer; 2008 Feb; 50(2):370-1. PubMed ID: 16652344
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
